Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7830383 | 0.91 | KDR (0.45) | CYP3A4ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL2646699 | 0.86 | KDR (0.54) | CYP3A4ALDH1A1MAOAMAOBKDR | |
| SCHEMBL7819821 | 0.86 | KDR (0.49) | ALDH1A1KDRNT5EHPGDFGFR1 | |
| SCHEMBL2643274 | 0.83 | KDR (0.44) | CYP3A4ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7820308 | 0.83 | FGFR1 (0.45) | CYP3A4ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL2648993 | 0.83 | CYP1A2 (0.48) | CYP3A4ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7828544 | 0.83 | ALDH1A1 (0.42) | CYP3A4ALDH1A1LMNATP53MAOA | |
| SCHEMBL6797821 | 0.83 | NT5E (0.47) | CYP3A4ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL2656192 | 0.83 | IDO1 (0.49) | CYP3A4ALDH1A1MAOAMAOBIDO1 | |
| SCHEMBL2643461 | 0.83 | IDO1 (0.40) | CYP3A4ALDH1A1MAOAMAOBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | claimed |
| EP-0821684-B1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2001-12-05 | — | — | EP | claimed |
| US-5922724-A | Benzimidazole compounds and their use as modulators of the GABA a receptor complex | NEUROSEARCH A/S (DK) | 1999-07-13 | — | — | US | claimed |
| EP-0821684-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1998-02-04 | — | — | EP | claimed |
| WO-1996033194-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | claimed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11485721-B2 | Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut (DE) | 2022-11-01 | — | — | US | disclosed |
| EP-4039258-A1 | USE OF DIAZEPAM AS ONLY TOLERATED BENZODIAZEPINE RECEPTOR AGONIST IN COVID-19 PATIENTS | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-08-10 | — | — | EP | disclosed |
| EP-4017874-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | Coda Biotherapeutics, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| EP-1164134-A1 | Benzimidazole compounds and their use as modulators of the GABA A receptor complex | NEUROSEARCH A/S (DK) | 2001-12-19 | — | — | EP | disclosed |
| EP-0821684-B1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2001-12-05 | — | — | EP | disclosed |
| US-5922724-A | Benzimidazole compounds and their use as modulators of the GABA a receptor complex | NEUROSEARCH A/S (DK) | 1999-07-13 | — | — | US | disclosed |
| EP-0821684-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033194-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485721-B2 | Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses | CBR3, POR, CYP2F1 | CYP3A4 52/4885ALDH1A1 809/4885LMNA 944/4885 |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CYP3A4 4884/4885ALDH1A1 4527/4885LMNA 797/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | CYP3A4 4869/4885ALDH1A1 4062/4885LMNA 1524/4885 |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | GABRB2, GABRA4, GABRB1 | CYP3A4 3639/4885ALDH1A1 1920/4885LMNA 4511/4885 |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CYP3A4 4884/4885ALDH1A1 4527/4885LMNA 797/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CYP3A4 4884/4885ALDH1A1 4527/4885LMNA 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.